U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease-February 2024-www.financetom.com

U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease

Apr 8, 2024 5:37 AM

April 8 (Reuters) - The U.S. Food and Drug

Administration (FDA) declined to approve Supernus

Pharmaceuticals' ( SUPN ) drug-device combination to treat

movement-related symptoms of Parkinson's disease, the drugmaker

said on Monday.

(Reporting by Puyaan Singh in Bengaluru; Editing by Shinjini

Ganguli)

Previous page： Eagle Bancorp's Q3 net loss of $67.5 mln misses analyst expectations Next page： Viking Therapeutics misses Q3 profit estimates

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Eagle Bancorp's Q3 net loss of $67.5 mln misses analyst expectations

Oct 22, 2025

Overview * Eagle Bancorp ( EGBN ) Q3 net loss of $67.5 mln, missing analyst expectations * Net interest income rose slightly to $68.2 mln, driven by lower funding costs * Noninterest income fell due to $3.6 mln loan sale loss and $2 mln security sale loss Outlook * Company did not provide specific guidance for future quarters or full...

Viking Therapeutics misses Q3 profit estimates

Oct 22, 2025

Overview * Viking Therapeutics ( VKTX ) reports Q3 net loss of $90.8 mln, missing analyst expectations * Company maintains strong cash position of $715 mln to support ongoing clinical trials * VK2735 Phase 2 VENTURE study shows up to 12.2% weight loss, meeting primary endpoints Outlook * Company expects to complete VANQUISH-1 enrollment by end of 2025 * Viking...

IT staffing firm ASGN Q3 adjusted EPS beats estimates on growth in consulting business

Oct 22, 2025

Overview * ASGN ( ASGN ) Q3 revenue was $1.01 bln, sligthly beating analyst expectations * Adjusted EPS for Q3 was $1.31, surpassing consensus estimates * Company repurchased 0.9 mln shares for $46 mln, reflecting confidence in financial position Outlook * Company expects Q4 2025 revenue between $960 mln and $980 mln * ASGN ( ASGN ) projects Q4 adjusted...

Kinder Morgan Q3 Adjusted Earnings, Revenue Increase

Oct 22, 2025

04:29 PM EDT, 10/22/2025 (MT Newswires) -- Kinder Morgan ( KMI ) reported Q3 adjusted earnings late Wednesday of $0.29 per share, up from $0.25 a year earlier. Analysts polled by FactSet expected $0.29. Revenue for the quarter ended Sept. 30 was $4.15 billion, up from $3.70 billion a year earlier. Analysts surveyed by FactSet expected $3.98 billion. Kinder Morgan...